Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical Business ReviewJascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Business Review Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPFNext: Regeneron immunotherapy combo comes up short in melanoma trial Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
